Advancing medicines to protect and restore hearing and silence tinnitus by funding translational research, creating partnerships, providing market insight and engaging patients.
In the UK there are 10 million people with a hearing loss and 6 million people who live with tinnitus. Despite this high medical need, there are no clinically approved treatments to halt or prevent hearing loss and no pharmaceutical treatment that can safely and effectively silence tinnitus.
TRIH aims to change this by supporting translational research – the phase of research where promising discoveries are moved from the laboratory into clinical trials. There are four key components to TRIH:
- Funding: supporting international translational research in hearing loss and tinnitus.
- Consultancy: providing expert advice and guidance to industry and investors on hearing loss and tinnitus research and development, and market opportunities.
- Partners: helping industry to work with leading research groups and therapy area experts around the world to accelerate the development of new therapeutics.
- Patients: helping people with hearing loss and tinnitus get involved in research.
More information about our TRIH services can be found in our TRIH Brochure or by contacting email@example.com